Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
References (9)
- Mansuri Z, Shah B, Trivedi C, et al. Opioid use disorder treatment and potential interactions with novel COVID-19 medications: a clinical perspective. Prim Care Companion CNS Disord. 2020;22(4):20com02703. PubMed CrossRef NLM
- Silva MJ, Kelly Z. The escalation of the opioid epidemic due to COVID-19 and resulting lessons about treatment alternatives. Am J Manag Care. 2020;26(7):e202–e204. PubMed CrossRef NLM
- Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol. 2020;127:104380. PubMed CrossRef NLM
- Atal S, Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharmaceut Med. 2020;34(4):223–231. PubMed NLM
- Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35(9):1687–1693. PubMed CrossRef NLM
- Actemra (tocilizumab) [prescribing information]. San Francisco, CA: Genentech Inc; 2011.
- Kevzara (sarilumab) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2017.
- Lee EB, Daskalakis N, Xu C, et al. Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet. 2017;56(6):607–615. PubMed CrossRef NLM
- Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–740. PubMed CrossRef NLM
Members enjoy free PDF downloads on all articles.
Save
Cite
Already a member? Login
Advertisement
GAM ID: sidebar-top